These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18229466)

  • 21. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is scleroderma an autoantibody mediated disease?
    Arnett FC
    Curr Opin Rheumatol; 2006 Nov; 18(6):579-81. PubMed ID: 17053501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrosis and immune dysregulation in systemic sclerosis.
    Chizzolini C; Brembilla NC; Montanari E; Truchetet ME
    Autoimmun Rev; 2011 Mar; 10(5):276-81. PubMed ID: 20863906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Systemic sclerosis--clinical course and treatment possibilities].
    Szymańska E; Maj M; Rudnicka L
    Przegl Lek; 2005; 62(12):1538-41. PubMed ID: 16786791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events.
    Chizzolini C
    Ann Med; 2007; 39(1):42-53. PubMed ID: 17364450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular pathways as novel therapeutic targets in systemic sclerosis.
    Trojanowska M; Varga J
    Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scleroderma: from cell and molecular mechanisms to disease models.
    Abraham DJ; Varga J
    Trends Immunol; 2005 Nov; 26(11):587-95. PubMed ID: 16168711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B cells in systemic sclerosis: a possible target for therapy.
    Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
    Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implication of oxidative stress in the pathogenesis of systemic sclerosis via inflammation, autoimmunity and fibrosis.
    Doridot L; Jeljeli M; Chêne C; Batteux F
    Redox Biol; 2019 Jul; 25():101122. PubMed ID: 30737171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [An update on systemic sclerosis].
    Kowal-Bielecka O
    Ann Acad Med Stetin; 2010; 56 Suppl 1():80-2. PubMed ID: 21365948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Systemic sclerosis--pathogenesis, clinical manifestations and treatment].
    Radić M; Kaliterna DM; Fabijanić D; Radić J
    Lijec Vjesn; 2010; 132(5-6):162-8. PubMed ID: 20677623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Physiopathology of scleroderma].
    Fleischmajer R; Perlish JS; Maquart FX; Kalis B
    Ann Dermatol Venereol; 1993; 120(2):157-66. PubMed ID: 8363310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis.
    Meiners S; Evankovich J; Mallampalli RK
    Transl Res; 2018 Aug; 198():17-28. PubMed ID: 29702079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.
    Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S
    Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of toll-like receptors in systemic sclerosis.
    Ciechomska M; Cant R; Finnigan J; van Laar JM; O'Reilly S
    Expert Rev Mol Med; 2013 Aug; 15():e9. PubMed ID: 23985302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic sclerosis/scleroderma: a treatable multisystem disease.
    Hinchcliff M; Varga J
    Am Fam Physician; 2008 Oct; 78(8):961-8. PubMed ID: 18953973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus.
    Khorshid O; Hosing C; Bibawi S; Ueno N; Reveille J; Mayes MD; Champlin RE
    J Rheumatol; 2004 Dec; 31(12):2513-6. PubMed ID: 15570660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Localized and systemic scleroderma.
    Hawk A; English JC
    Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic sclerosis.
    Allanore Y; Simms R; Distler O; Trojanowska M; Pope J; Denton CP; Varga J
    Nat Rev Dis Primers; 2015 Apr; 1():15002. PubMed ID: 27189141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Animal models of systemic sclerosis.
    Morin F; Kavian N; Batteux F
    Curr Pharm Des; 2015; 21(18):2365-79. PubMed ID: 25777753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.